Presented by presented by
Gilead shatters records, sets historic mark with launch of Sovaldi
Jeffrey Clark - Posted: 4/23/2014
Gilead Sciences has the tiger by the tail with the launch of its new Hepatitis C drug, Sovaldi.  With yesterday’s earnings report, Sovaldi is now the fastest and most successful drug launch ever logging roughly $2.5B in sales for its first quarter on[...]
Seismic shift in Big Pharma with Novartis, GSK, Lilly taking part in huge deal
Jeffrey Clark - Posted: 4/22/2014
Why did we create Beaker?  For days like today. While most life sciences professionals are hard at work or in meeting today, a seismic shift has occurred to virtually reshaped the entire pharmaceutical industry.  Aside from the $100B offer from Pfize[...]
Valeant secretly acquires 10% of Allergan, will make hostile bid
Jeffrey Clark - Posted: 4/22/2014
Valeant and its powerful financiers are making a bid to double in size by acquiring Allergan in a hostile acquisition. Valeant has a strong partnership with Valueact Capital.  And in concert with Bill Ackmans Pershing Square Capital, they have amasse[...]
Pfizer, Astrazeneca rumored to be courting $100B merger
Jeffrey Clark - Posted: 4/21/2014
Pfizer may be trying to buy the struggling pharma giant AstraZeneca more than $100B, setting the stage for what could be the first Big Pharma megamerger in almost 10 years. Predictably, Pfizer will not comment.  However, a variety of sources saying t[...]
Google Glass as a medical device?
Jeffrey Clark - Posted: 4/17/2014
A round of venture capital financing from Emergence Capital Partners and DCM has brought in $3.2 million for Augmedix. Augmedix is a Bay area startup which is hoping to develop the yet-to-be-launched Google Glass for use in clinical care, initially f[...]
Covidien CEO Almeida takes over as new Chairman for Advamed
Jeffrey Clark - Posted: 4/16/2014
Covidien President and CEO Jose Almeida will serve as Advameds Chairman for the next two years, following in the footsteps of Dave Dvorak from Zimmer.  Stephen Ubl is Advameds leader, while the Chairman role gets rotated amongst prominent CEOs from t[...]
FDA watching China more closely, with two inspectors
Jeffrey Clark - Posted: 4/15/2014
Chinese makers of pharmaceutical ingredients are coming under increasing scrutiny from the FDA in an effort to bolster the safety of the U.S. drug supply chain, Christopher Hickey, director of the FDAs office in China, said Thursday at a hearing in W[...]
Crowdfunding for clinical trials? Yes, crowdfunding for clinical trials.
Jeffrey Clark - Posted: 4/14/2014
Crowdfunding may be foreign to many in the life sciences industry.  The practice involves the collection of finances to fund an initiative from a large pool of backers usually online.  The concept was born from nonprofit, political, philanthropic and[...]
Cool technology: FDA approves device for heroin overdose victims
Jeffrey Clark - Posted: 4/11/2014
The FDA has approved Evzio, a auto-injecting opioid overdose treatment.  The product is a naloxone hydrochloride injection from a Virginia-based company called Kaleo.  Because heroin overdoses tend to be a chaotic scene (we assume), the device can be[...]
Takeda and Lilly hammered by Actos verdict, $9B in damages
Jeffrey Clark - Posted: 4/10/2014
Takeda and Eli Lilly were ordered to pay a combined $9 billion in punitive damages after a federal court jury found they hid the cancer risks of their Actos diabetes medicine in the first U.S. trial of its kind.   A jury in Lafayette, LA ordered Take[...]
Daiichi Sankyo drops Ranbaxy in merger deal with Sun Pharma
Jeffrey Clark - Posted: 4/8/2014
Daiichi Sankyo has decided to sell Ranbaxy to Sun Pharma.   The deal will make Sun Pharma the leading company in the highly fragmented Indian market, ahead of Abbott.   It also makes Sun the fifth-largest generics company in the world.   Ranbaxy has [...]
Drug research spending remains, but risk is significant
Jeffrey Clark - Posted: 4/7/2014
Roche, Novartis and Johnson & Johnson topped Genetic Engineering & Biotechnology News ranking of biopharmaceutical companies based on research and development spending last year.  Merck and Pfizer took the fourth and fifth spots, respectively.   Also[...]
Orphan drugs set record in 2013
Jeffrey Clark - Posted: 4/4/2014
The FDA approved 31 orphan drugs last year, the highest number since the Orphan Drug Act was signed into law in 1983. A total of 260 orphan-drug designations were awarded last year, while orphan-designation requests reached 346, both breaking record [...]
MannKind: If at first you dont succeed
Jeffrey Clark - Posted: 4/2/2014
This has been a long time a comin for the southern California-based medical device maker. An FDA advisory panel has endorsed the approval of MannKinds inhaled insulin therapy, branded as Afrezza, as a treatment for both types of diabetes.  Afrezza co[...]
BMS, Roche and Merck race to deliver first immunotherapy for melanoma
Jeffrey Clark - Posted: 4/1/2014
With GSK having failed in its latest trial, BMS, Roche and Merck are now racing to develop an immunotherapy treatment for advanced melanoma, hoping to get the treatments approved and launched within about the next 18 months.  AstraZeneca is also targ[...]
CEO of Cardinal Health on CNBC discussing Obamacare
Jeffrey Clark - Posted: 3/31/2014
It is not often that we hear publicly from George Barrett, CEO of Cardinal Health. Last week, he was on CNBC discussing how Obamacare is prompting change within the health care industry.
Lilly freezes pay, cuts bonuses as revenue cliff approaches
Jeffrey Clark - Posted: 3/27/2014
Eli Lilly has announced that the company will freeze current salaries for most employees, in an attempt to reduce expenses as patent expirations for key drugs are hurting sales. The company will also reduce cash-bonus targets for most of its 38,000 g[...]
Enter the realm of the biohacker
Jeffrey Clark - Posted: 3/26/2014
Ever heard of a biohacker?  Well, emerging across the fringes of the life sciences industry are organizations built to fuel the research of free-thinking independent scientists.   BIocurious, Berkeley Biolabs, Genspace and Counter Culture Labsjust to[...]
The role of Big Data in the life sciences industry
Jeffrey Clark - Posted: 3/24/2014
Big Data is all the rage right now.  Companies from virtually every industry are betting that analytics can help them better manage their businesses and drive growth. The life sciences industry is no different.  A McKinsey study found that drugmakers[...]
Cool technology: Wearable medical device to prevent migraines
Jeffrey Clark - Posted: 3/21/2014
The FDA has approved a medical device designed to prevent migraine headaches. The Cefaly is a small, wearable headband which delivers an electrical current to stimulate the trigeminal nerve, commonly connected to migraine headaches. The device requir[...]
Gilead proves doubters wrong, new HepC drug trending like a rocket ship
Jeffrey Clark - Posted: 3/20/2014
Why do you pay $11B for a company with 80 employees, no revenues and a promising Hepatitis C product in Phase II trials?  This is why. Analysts who once questioned Gileads acquisition of Pharmasset, are now predicting that the companys new Hepatitis [...]
Olympus closing US biotechnology business, selling facility
Jeffrey Clark - Posted: 3/19/2014
Japanese tech giant Olympus is shuttering its U.S. biotechnology  business and looking to sell off the New Hampshire plant that makes the OP-1 bone growth putty, leading to layoffs for some 200 workers.  The OP-1 putty caused a major headache for Str[...]
Life sciences and venture capital. Where does your city rank?
Jeffrey Clark - Posted: 3/17/2014
FierceBiotech has a fantastic article about the geographic source of venture capital deals in biotechnology last year. More than anything, this paints an accurate portrait of where the startup life sciences industry resides around the US. FierceBiote[...]
Craig Venter sets his sights on aging with Human Longevity
Jeffrey Clark - Posted: 3/14/2014
Synthetic Genomics CEO Dr. J. Craig Venter, in partnership with stem cell pioneer Dr. Robert Hariri and X Prize Foundation CEO Dr. Peter Diamandis, has launched a new company named Human Longevity to develop new genomics and stem cell-based treatment[...]
Durham-based Chimerix to help ailing child with compassionate plea
Jeffrey Clark - Posted: 3/12/2014
For the past few days, Durham-based drug company Chimerix has been fighting a losing public battle.  Josh Hardy is a 7-year old who has been fighting cancer virtually his entire life.  Joshs journey began when he was diagnosed with a rare form of kid[...]
Valeant secretly acquires[...]
Valeant and its powerful financiers are making a bid to double in size by acquiring Allergan in a ho[...]
BeakerBeat - 04-21-14
Seems like everyone is expanding in the Chinese pharma market, except the agency performing safety i[...]
BeakerBeat - 04-14-14
The HHS gets a sudden switch at the top spot – who is replacing Kathleen Sebelius and why many feel [...]
Daiichi Sankyo drops Ranb[...]
Daiichi Sankyo has decided to sell Ranbaxy to Sun Pharma. The deal will make Sun Pharma the leadin[...]
BeakerBeat - 04-07-14
Just like when Augusta National made the course harder on players for the Masters, China is making i[...]